U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07218887) titled 'ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy' on Oct. 17.
Brief Summary: This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
Study Start Date: Dec. 31
Study Type: INTERVENTIONAL
Condition:
BAG3 Mutation Associated Dilated Cardiomyopathy
Intervention:
DRUG: ALXN2350
ALXN2350 is a gene therapy product consisting of an AAV9 capsid containing BAG3 transgene. It is administered as a single intravenous (IV) infusion.
Recruitment Status: NOT_Y...